Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M

CUMBERLAND PHARMACEUTICALS INC

Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.
Full-year net loss $6.4M; adjusted loss $1.0M (excl. $1.3M product acquisition costs).
Cash $18M, total assets $76M, liabilities $53M, shareholders' equity $23M at year-end.
Phase 2 ifetroban DMD study positive top-line; Vibativ approved in China.
Kristalose $15.3M, Sancuso $9M, Vibativ $7.2M, Caldolor $5M in 2024 revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.